Related Experiment Video
Updated: May 2, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
12.8K
Clinical pharmacogenetics implementation: approaches, successes, and challenges
Summary
The University of Florida
Area of Science:
- Genomic Medicine
- Pharmacogenetics
- Clinical Implementation
Background:
- Genomic medicine and pharmacogenetics face challenges in widespread clinical adoption.
- The University of Florida (UF) Health Personalized Medicine Program (PMP) was established in 2011 as a pharmacist-led initiative.
- Initial focus was on pharmacogenetics, with future aims for disease-risk prediction and stratification.
Purpose of the Study:
- To describe the development process of the UF PMP.
- To outline challenges encountered during program implementation.
- To assess clinical acceptance of genomic medicine integration.
Main Methods:
- Initiated clinical implementation in June 2012, targeting clopidogrel use and CYP2C19 genotype in patients undergoing left heart catheterization and percutaneous-coronary intervention (PCI).
- Preemptively genotyped 1,097 patients undergoing left heart catheterization.
- Tracked genotype results, actionable genotypes, drug therapy changes, turnaround times, and reimbursement rates.
Main Results:
- 1,097 patients were genotyped, with 291 undergoing PCI.
- 80 patients had actionable genotypes, leading to 56 drug therapy modifications.
- Average turnaround time was 3.5 business days; 85% reimbursement rate achieved in the first month.
Conclusions:
- The UF PMP demonstrated successful clinical implementation of genomic medicine.
- Pharmacist-led initiatives can effectively integrate pharmacogenetics into clinical practice.
- The program achieved significant clinical acceptance and positive reimbursement outcomes.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
6.5K
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
9.2K
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:29Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338